Literature DB >> 16611089

Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update.

Thomas Steckler1, Frank M Dautzenberg.   

Abstract

Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF(1) and CRF(2)) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF(1) and CRF(2) receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF(1) antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF(1) receptor and the generation of peptide-based research tools, the physiological role of the CRF(2) receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brain-penetrant CRF(2)-selective small molecule antagonists. However, the CRF(2) receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611089     DOI: 10.2174/187152706776359619

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  18 in total

Review 1.  Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.

Authors:  Yvette Taché; Bruno Bonaz
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects.

Authors:  Mark E Schmidt; Randolph D Andrews; Peter van der Ark; Terry Brown; Erik Mannaert; Thomas Steckler; Jan de Hoon; Koen Van Laere
Journal:  Psychopharmacology (Berl)       Date:  2009-11-13       Impact factor: 4.530

Review 3.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 4.  Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism.

Authors:  Emily G Lowery; Todd E Thiele
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

5.  Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.

Authors:  Fumikazu Yokoyama; Miki Yamauchi; Masayo Oyama; Kunihiro Okuma; Kaname Onozawa; Takako Nagayama; Rie Shinei; Makoto Ishikawa; Yasuo Sato; Nobukazu Kakui
Journal:  Psychopharmacology (Berl)       Date:  2009-04-09       Impact factor: 4.530

Review 6.  Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders.

Authors:  Wolfgang H Sommer; Juan M Saavedra
Journal:  J Mol Med (Berl)       Date:  2008-05-01       Impact factor: 4.599

7.  CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD.

Authors:  Robert Adamec; Dennis Fougere; Victoria Risbrough
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

8.  Expression, binding, and signaling properties of CRF2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors.

Authors:  Eric Gutknecht; Richard L Hauger; Ilse Van der Linden; Georges Vauquelin; Frank M Dautzenberg
Journal:  J Neurochem       Date:  2007-11-01       Impact factor: 5.372

Review 9.  Removing obstacles in neuroscience drug discovery: the future path for animal models.

Authors:  Athina Markou; Christian Chiamulera; Mark A Geyer; Mark Tricklebank; Thomas Steckler
Journal:  Neuropsychopharmacology       Date:  2008-10-01       Impact factor: 7.853

10.  Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice.

Authors:  Cedomir Todorovic; Tessi Sherrin; Matthew Pitts; Cathrin Hippel; Martin Rayner; Joachim Spiess
Journal:  Neuropsychopharmacology       Date:  2008-10-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.